Hrt Financial LP Zynerba Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.33 - $1.39 $67,065 - $282,488	203,229 New	203,229 $258,000
Q1 2023 May 12, 2023	BUY	$0.4 - $0.67 $7,904 - $13,239	19,760 New	19,760 $8,000
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $28,398 - $44,393	32,642 New	32,642 $23,000
Q2 2022 Aug 12, 2022	SELL	$0.86 - $2.06 $11,982 - $28,701	-13,933 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $25,497 - $42,077	13,933 New	13,933 $28,000
Q3 2021 Nov 15, 2021	SELL	$3.72 - $5.35 $138,529 - $199,228	-37,239 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.83 - $5.98 $101,403 - $158,326	-26,476 Reduced 41.55%	37,239 $196,000
Q1 2021 May 17, 2021	BUY	$3.33 - $8.76 $212,170 - $558,143	63,715 New	63,715 $296,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.